Literature DB >> 12519632

Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity.

Lucio G Costa1, Rebecca J Richter, Wan-Fen Li, Toby Cole, Marina Guizzetti, Clement E Furlong.   

Abstract

Paraoxonase (PON1) is an A-esterase capable of hydrolysing the active metabolites (oxons) of a number of organophosphorus (OP) insecticides such as parathion, diazinon and chlorpyrifos. PON1 activity is highest in liver and plasma, and among animal species significant differences exist, with birds and rabbits displaying very low and high activity, respectively. Human PON1 has two polymorphisms in the coding region (Q192R and L55M) and five polymorphisms in the promoter region. The Q192R polymorphism imparts different catalytic activity toward some OP substrates, while the polymorphism at position -108 (C/T) is the major contributor to differences in the level of PON1 expression. Animal studies have shown that PON1 is an important determinant of OP toxicity, with animal species with a low PON1 activity having an increased sensitivity to OPs. Administration of exogenous PON1 to rats or mice protects them from the toxicity of OPs. PON1 knockout mice display a high sensitivity to the toxicity of diazoxon and chlorpyrifos oxon, but not paraoxon. In vitro assayed catalytic efficiencies of purified PON(192) isoforms for hydrolysis of specific oxon substrates accurately predict the degree of in vivo protection afforded by each isoform. Low PON1 activity may also contribute to the higher sensitivity of newborns to OP toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519632     DOI: 10.1080/13547500210148315

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  38 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

2.  Prenatal exposure to organophosphate pesticides, maternal paraoxonase 1 genotype, and childhood neurodevelopment at 24 months of age in Shandong, China.

Authors:  Yiwen Wang; Yan Zhang; Lin Ji; Yijun Zhou; Rong Shi; Michihiro Kamijima; Jun Ueyama; Yu Gao; Ying Tian
Journal:  Environ Sci Pollut Res Int       Date:  2019-11-25       Impact factor: 4.223

Review 3.  Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children's environmental health.

Authors:  Nina Holland; Daneida Lizarraga; Karen Huen
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

4.  PON1 status does not influence cholinesterase activity in Egyptian agricultural workers exposed to chlorpyrifos.

Authors:  Corie A Ellison; Alice L Crane; Matthew R Bonner; James B Knaak; Richard W Browne; Pamela J Lein; James R Olson
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-10       Impact factor: 4.219

5.  Delayed reduction of hippocampal synaptic transmission and spines following exposure to repeated subclinical doses of organophosphorus pesticide in adult mice.

Authors:  Haley E Speed; Cory A Blaiss; Ahleum Kim; Michael E Haws; Neal R Melvin; Michael Jennings; Amelia J Eisch; Craig M Powell
Journal:  Toxicol Sci       Date:  2011-09-26       Impact factor: 4.849

Review 6.  Research Review: Environmental exposures, neurodevelopment, and child mental health - new paradigms for the study of brain and behavioral effects.

Authors:  Virginia A Rauh; Amy E Margolis
Journal:  J Child Psychol Psychiatry       Date:  2016-03-14       Impact factor: 8.982

Review 7.  Mass spectrometric analyses of organophosphate insecticide oxon protein adducts.

Authors:  Charles M Thompson; John M Prins; Kathleen M George
Journal:  Environ Health Perspect       Date:  2010-01       Impact factor: 9.031

8.  Regulation of FMO and PON detoxication systems in ALS human tissues.

Authors:  Stella Gagliardi; Kenneth Abel; Marika Bianchi; Pamela Milani; Stefano Bernuzzi; Manuel Corato; Mauro Ceroni; John R Cashman; Cristina Cereda
Journal:  Neurotox Res       Date:  2012-10-17       Impact factor: 3.911

Review 9.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure.

Authors:  Pei-Chen Lee; Shannon L Rhodes; Janet S Sinsheimer; Jeff Bronstein; Beate Ritz
Journal:  Environ Int       Date:  2013-04-16       Impact factor: 9.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.